Tumor microbiota is the collective of microorganisms residing in the tumor microenvironment that are involved in cancer biology. The session "Tumor Microbiota" discusses how the microbial populations affect tumor development, immune reactions, and therapy responses.".
Studies have indicated that the make-up of tumor-associated microbiota can influence cancer development, regulate inflammation, and influence the therapeutic effect of chemotherapy, immunotherapy, and targeted therapy. Some bacteria have been found to facilitate tumorigenesis while others support anti-tumor immunity, thus research in tumor microbiota is vital for the generation of novel therapeutic approaches.
This session discusses strategies for HPA-tumor-associated microbial profiling using metagenomics, 16S rRNA sequencing, and sophisticated bioinformatics analyses. Insight into the relationship between microbiota, tumor cells, and immunity can inform precision medicine strategies, including microbiome-targeted therapy, probiotics, or microbial modulation to enhance therapeutic response.
Participants will learn how tumor microbiota is involved in the initiation, growth, and drug resistance of cancer. The session highlights how making use of microbiota information will enhance individualized treatment models, maximize therapeutic efficacy, and create new paths for novel cancer therapies within precision oncology.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
